Previous close | 0.1291 |
Open | 0.1286 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.1240 - 0.1300 |
52-week range | 0.0300 - 0.1500 |
Volume | |
Avg. volume | 1,685,216 |
Market cap | 129.381M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0000 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Company Implementing Next Phase of Its Recombinant Spider Silk Business PlanANN ARBOR, Mich., May 09, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that the spring production trials of the Company's new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness. Kraig Labs reports that the spring production trials were an unabashed success. These trials proved that the
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), announces today that it has signed key agreements with the Lam Dong Agro-Forestry Research Experiment Center ("LAREC"), the sericulture authority in central Vietnam, pertaining to the rearing and breeding of the Company's specialized silkworm. Within these agreements, Kraig Labs outlined its operational plans for expansion. These agreements outline a collaborative working effort
ANN ARBOR, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial. Kraig Labs has successfully produced cocoon at rates that exceeded all expectations and control parameters for these trials. Under the supervision and guidance of a top indepe